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INTRODUCTION
Peroxisome proliferator-activated receptor alpha
(PPARα) is a ligand activated transcription factor
and has an important role in lipid homeostasis (1).
Following activation by its endogenous/exogenous
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Amaç: Hepatosellüler kanserlerin gelifliminde PPARα ’n›n ro-
lüne iflaret eden birçok kan›t mevcuttur. PPARα geninin L162V
polimorfizmi bu transkripsiyon faktörünün transaktivasyonu-
nu artt›r›r. Bu çal›flman›n amac› hepatit virüsü enfeksiyonu ze-
mininde geliflmifl hepatosellüler kanser hastalar›nda PPAR·
L162V polimorfizminin s›kl›¤›n›n ve bu mutasyonun klinik se-
yir ile iliflkisinin araflt›rmas›d›r. Yöntem: Ankara Üniversitesi
Gastroenteroloji Klini¤inde Ocak 2002 – Temmuz 2003 tarihle-
ri aras›nda tan› alm›fl ve 90 hepatosellüler kanserlerin hastas›
ve 80 sa¤l›kl› kontrol (normal beden kitle indeksi, kan biyokim-
yas› olan ve viral serolojisi negatif olan) çal›flmaya al›nd›.
PPAR· L162V polimorfizmi PZR-RFLP yöntemi ile tespit edil-
di. Bulgular: Hastalar›n etyolojileri, 56 HBV, 12 HBV+HDV,
22 HCV olarak tespit edildi. 87 hasta(%97) sirotikti ve 60 has-
tan›n (%67.5) tümörü ileri evredeydi. 83 hastada (%92-50 HBV,
12 HBV+HDV, 21 HCV) PPAR· geninin polimorfik bölgesini
PZR ile amplifiye edilebildi. Bu hastalar›n 6’s›nda (%7,2- ta-
mam› HBV) L162V polimorfizmi tespit edilirken, kontrol hasta-
lar›n›n 2’sinde (%2,5-p=0,162) bu polimorfizm tespit edildi. Bu
trendin HBV+HDV olan hastalar ile kontroller karfl›laflt›r›ld›-
¤›nda daha belirgin oldu¤u (6/62, %9.2 – 2/80 %2.5, p=0.071).
L162V polimorfizmi olan hastalardan 5 ‘inde ileri evre hastal›k
mevcuttur. Sonuç: PPAR· geninin L162V polimorfizmi HBV ile
iliflkili hepatosellüler kanserde görülürken HCV zemininde ge-
liflenlerde görülmemektedir. Bu bulgular farkl› iki etyoloji ze-
mininde geliflen hepatosellüler kanserlerin karsinogenetik me-
kanizmalar›n farkl› olabilece¤ini düflündürmektedir. L162V
polimorfizmi olan hastalardaki Hepatosellüler kanserin ileri
evrede olmas› bu polimorfizmin hastal›¤›n progresyonunu etki-
ledi¤ini düflündürmektedir.
Anahtar kelimeler: PPARα, L162V, polimorfizm, hepatit C virü-
sü, Hepatit B virüsü, hepatosellüler kanser
Background/aims: Several lines of evidence suggest that pero-
xisome proliferator-activated receptor alpha may be involved in
hepatocarcinogenesis. L162V polymorphism of the peroxisome
proliferator-activated receptor alpha gene enhances the transac-
tivation activity of this transcription factor. The aim of this study
was to determine the frequency and clinical correlates of peroxi-
some proliferator-activated receptor alpha L162V polymorphism
in hepatitis virus-induced hepatocellular carcinoma. Methods:
90 hepatocellular carcinoma patients diagnosed at Ankara Uni-
versity Gastroenterology Clinic between January 2002 and July
2003 and 80 healthy controls with normal body mass index, blo-
od chemistry and with negative viral serology were included. pe-
roxisome proliferator-activated receptor alpha L162V polymorp-
hism was determined by PCR-RFLP. Results: hepatocellular
carcinoma etiologies were as follows: 56 HBV, 12 HBV+HDV, 22
HCV. Eighty-seven patients (97%) were cirrhotic, and 60 patients
(67.5%) had advanced tumors. In 83 (92%) of 90 hepatocellular
carcinoma patients, gene segment including polymorphic region
could be amplified by PCR (50 HBV, 12 HBV+HDV, 21 HCV)
and 6 of them (7.2%, all infected with HBV) had L162V poly-
morphism, while 2 (2.5%) of 80 controls had this polymorphism
(p=0.162). This trend became more remarkable when only HBV
(HBV+HDV)-infected patients were compared with controls
(6/62, 9.7% vs. 2/80, 2.5%, respectively, p=0.071). Five of 6 pati-
ents with L162V had advanced disease. Conclusions: Peroxiso-
me proliferator-activated receptor alpha L162V polymorphism
tends to occur in HBV-induced epatocellular carcinoma and is
absent in HCV-related epatocellular carcinoma. These findings
may show clues for the existence of different carcinogenesis mec-
hanisms in these two common etiologies. Frequent occurrence of
advanced disease in patients with L162V polymorphism suggests
a role for this polymorphism in tumor progression.
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ligands, PPARα forms a heterodimer with the 9-
cis-retinoic acid receptor (RXR), and PPAR/RXR
heterodimers bind to DNA sequences, termed
PPAR response elements (PPRE), present in the
5´-flanking region of target genes (2-4). PPARα in-
duces fatty acid oxidation in mitochondria, peroxi-
somes and microsomes (1, 5), and there appears to
be a cross-talk between these three fatty acid oxi-
dation systems, with PPARα playing a controlling
role (1, 6-9).
Hepatitis viruses are the main cause of human he-
patocellular carcinoma (HCC). Although the mec-
hanism of human tumor development is not comp-
letely understood, chronic injury and subsequent
hepatocyte regeneration as well as oncogenic po-
tentials of viral proteins are thought to be respon-
sible for tumor development (10, 11). The role of
host factors in HCC development is less clear. Se-
veral lines of evidences suggest that PPARα may
be involved in carcinogenesis (12, 13). Hypolipide-
mic peroxisome proliferators, well known PPARα
activators, have been shown to cause liver tumors
in mice and rats (14). Knock-out animal experi-
ments also point to the role of PPARα-inducible
fatty acid oxidation systems in the pathogenesis of
liver tumor development. Disruption of the PPARα
gene in mice causes liver steatosis by reducing mi-
tochondrial fatty acid oxidation, while dramatic
activation of PPARα by disruption of peroxisomal
acyl CoA oxidase leads to steatohepatitis and liver
cell tumors (15-17). 
Recently, a polymorphism in the PPARα gene, le-
ucine to valine change at codon 162 localized to
exon 5 (L162V), has been described (18, 19). This
polymorphism was shown to enhance the trans-
criptional activity of PPARα in transfection assays
(18). PPARα L162V polymorphism has been repor-
ted to be associated with altered lipid and apobe-
talipoprotein concentrations and with an increa-
sed body mass index (BMI) (18-21). These associ-
ations raised the possibility that this polymorp-
hism may be associated with non-alcoholic steato-
hepatitis (NASH), which may result in liver cirr-
hosis and hepatoma. However, our recent study
did not show a link between NASH and PPARα
L162V polymorphism (22). On the other hand,
only a minority of human HCCs are due to NASH,
and most are caused by hepatitis viruses.
Thus far, there has been no study addressing an
association between PPARα L162V polymorphism
and human HCC development. In this study, we
aimed to determine the frequency and clinical cor-
relates of PPARα L162V polymorphism in human
HCC, which is mainly induced by hepatitis viruses.
MATERIALS AND METHODS
Study samples and data collection
Ninety HCC patients (77 M, 13 F) infected with
hepatitis viruses diagnosed in Ankara University
Gastroenterology Clinic between January 2002
and July 2003 were included. None of the patients
had any other identifiable causes of HCC and alco-
hol intake was absent or less than 20 g per week
in all of these patients. None of the patients had a
BMI greater than 30. In addition, none of the pa-
tients had any evidence of systemic disease inclu-
ding collagen-vascular, neoplastic, cardiopulmo-
nary or renal disease. Eighty healthy subjects (44
M, 36 F) with normal BMI, normal blood che-
mistry and negative viral serology served as con-
trols. 
Presence or absence of cirrhosis and Child score of
the cirrhotic patients were recorded. The diagno-
sis of HCC was based on detection of liver tumors
by two different radiological visualizations in the
presence of elevated alpha fetoprotein level or
cytological/histological assessment of tumor tissu-
e by examination of percutaneous biopsy sample
or resection material obtained during resecti-
on/transplantation procedures. Advanced tumor
was defined as total tumor size ≥ 8 cm or multifo-
cal/diffuse tumors without portal vein thrombosis
or distant metastasis. A single solitary tumor <6.5
cm or ≤3 tumors with none >4.5 cm and a total tu-
mor size <8 cm at presentation was accepted as
less advanced tumor according to University of
California at San Francisco (UCSF) criteria (23).
Detection of PPARα L162V polymorphism
A blood sample was drawn from each patient and
from healthy controls for DNA isolation. Cellular
DNAs were kept at -20°C until polymerase chain
reaction (PCR) analysis. In the mismatch PCR,
the following primers generating HinfI restriction
site were used for further RFLP analysis (18):
Ex 5 F 5´ GAC TCA AGC TGG TGT ATG ACA
AGT 3´
Ex 5 R mismatch 5´ CGT TGT GTG ACA TCC
CGA CAG AAT 3´ (T: mismatch nucleotide).
Following preparation of 1.25 U Taq polymerase,
2.5 mM MgCl and 0.2 mM dNTP, forward and re-
verse primers (10 pmol each) were added. The fi-
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nal volume of the reaction was adjusted to 50 µl.
The annealing temperature of the reaction was
61°C. Following application of HinfI endonuclease
enzyme to PCR products, while a 117 bp band was
visualized for a normal allele, two separate bands
of 93 bp and 24 bp were observed for a mutant al-
lele on 2% agarose gel electrophoresis (Figure 1).
RESULTS
Patient characteristics
Table 1 shows the clinical characteristics of HCC
patients at the time of the diagnosis. Male predo-
minance was observed in the patient cohort.
Eighty-seven patients (97%) were cirrhotic, most
of whom (80%) were at Child B or C stage. 
Hepatocellular carcinoma etiologies were as fol-
lows: 56 (62.2%) HBV, 12 (13.3%) HBV+HDV, and
22 (24.5%) HCV. Sixty patients (67.5%) had ad-
vanced tumors (total tumor size ≥ 8 cm or multifo-
cal/diffuse tumors w/o portal vein thrombosis or
distant metastasis), while 30 (33.5%) patients had
less advanced tumors. Seven patients had distant
metastases (2 bone, 5 lung).
Frequency and clinical correlates of L162V
polymorphism
In 83 (92%) of 90 HCC patients, gene segment inc-
luding polymorphic region could be amplified by
PCR.  HCC etiologies of these 83 patients were as
follows: 50 (60%) HBV, 12 (14.5%) HBV+HDV and
21 (25.5%) HCV. Six of 83 (7.2%) patients had
L162V polymorphism, while only 2 (2.5%) of 80
controls had this polymorphism (p=0.162). This
trend became more remarkable when only HBV
(HBV+HDV)-infected patients were compared
with controls (6/62, 9.7% vs. 2/80, 2.5%, respecti-
vely, p=0.071) (Table 2). In fact, all of the 6 pati-
ents who had L162V polymorphism were infected
with HBV (5 HBV alone, 1 HBV+HDV) and none
of the HCV-infected patients had this polymorp-
hism (Table 3). Interestingly, 5 of these 6 cases
(83.3%) had advanced disease (Table 3) and all of
them had a normal BMI.  
DISCUSSION
PPARα is a key regulator of fatty acid oxidation
and plays important roles in lipid metabolism.
Animal experiments suggest that it may also have
some roles in liver tumor development, although
possible mechanisms for tumor promotion are not
well understood. PPARα may induce tumor deve-
lopment by inhibiting apoptosis, interacting with
growth control genes and enhancing H2O2 pro-
duction by stimulation of peroxisome proliferation
(12, 13). Genetic or acquired variations in expres-
sion and activity of this molecule may have an im-
pact on several physiological and pathological con-
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Cirrhotic patients 87 97
Child-Pugh A 17 19.5
Child-Pugh B 34 39
Child-Pugh C 36 41.5
Non-cirrhotic patients 3 3 
Etiology of HCC
HBV 56 62.2
HBV+HDV 12 13.3 
HCV 22 24.5          
Disease stage
Advanced tumor 60 67.5
- Distant metastasis 7 8 
Non-advanced tumor 30 33.5
Table 1. Characteristics of HCC patients
No. of No. of patients
Etiology Patients with L162V L162V%
HBV 62 6 9.7
HBV alone 50 5 10
HBV+HDV 12 1 8.3
HCV 21 0 0
Controls 80 2 2.5
HBV vs HCV, p=0.163 HBV vs Controls, p=0.076
HBV+HDV vs HCV, p=0.163 HBV+HDV vs Controls, p=0.071
Table 2. Frequency of L162V in different etiologies
Figure 1. Gel electrophoresis showing several cases with a sing-
le band of normal alleles (L162L) and with two bands of mutant
alleles (L162V)
ditions. L162V polymorphism of the PPARα gene
was reported to enhance transactivation function
but not increase the expression of this molecule
(27). This polymorphism has been found to be as-
sociated with several in vivo lipid and apolipopro-
tein abnormalities (18-21), but its role in human
cancers has not been explored yet. This study rep-
resents the first investigating the role of this poly-
morphism in human HCC. 
PPARα L162V polymorphism tended to more fre-
quently occur in HCC patients compared to he-
althy controls. Interestingly, this trend was more
significant in HBV-related HCC patients. Altho-
ugh the present study included a total of 90 HCC
patients, this sample size may not be enough to re-
ach a statistical significance because of the low
frequency of L162V polymorphism. In addition,
the present study included a heterogeneous pati-
ent population consisting of both HBV- and HCV-
related HCC cases. In fact, L162V polymorphism
was more frequently observed in HBV-related
HCC patients, and this trend was not observed in
HCV-related HCC patients. Interestingly, all pati-
ents carrying L162V polymorphism were infected
with HBV and none of the HCV-infected patients
had this polymorphism. These findings may be
clues for the existence of different carcinogenesis
mechanisms in these two common etiologies.
Associations of this polymorphism with several
pathological alterations may be limited to some
specific conditions. This can be exemplified by the
finding that L162V polymorphism may be associa-
ted with some specific lipid abnormalities and
BMI only in diabetic patients (18-21, 24). In fact,
L162V polymorphism was not found to be associa-
ted with blood lipid abnormalities nor with BMI in
healthy controls and patients with coronary heart
disease (18-21, 25). Similarly, L162V and HCC as-
sociation may be restricted to HBV-induced HCC
cases. Variations in the expression and/or the ac-
tivity of PPARα, its ligands and PPRE and their
regulators in different diseases and in different
conditions may diversely affect the outcome of the-
se diseases. Presence of a variant PPARα molecu-
le may render HBV-infected patients prone to
HCC development.
The potential mechanism(s) of L162V polymorp-
hism and HBV-induced HCC association are not
clear. PPARα has been shown to interact with
HBV X-associated protein2 (26). In addition, RXR-
PPARα heterodimer may transactivate enhancer
1 of HBV (27). Such a viral protein/regulatory se-
quence and PPARα/PPRE interaction may alter
the cellular responses to PPARα and/or HBV viral
proteins. Furthermore, variations in PPARα gene
(e.g. L162V polymorphism) may change these res-
ponses and may facilitate tumor development. In
addition, gene activation status and expression of
growth control molecules, and malignant cell res-
ponses to exogenous/endogenous stimuli may be
different in HBV- and HCV-induced HCC. Presen-
ce of several variant host proteins (e.g. L162V)
may promote cancer development in selected con-
ditions (e.g. HBV-induced disease). Further studi-
es are needed to clarify whether PPARα interacts
with several viral and cellular proteins that may
result in tumor promotion and progression. 
Another interesting finding of the present study
was that most patients with L162V polymorphism
had advanced tumors. Although this might be re-
lated with the small number of patients having
this polymorphism, change in transactivation
function of PPARα may lead to more aggressive
tumor behavior. This latter speculation must be
cautiously interpreted and needs to be investiga-
ted with further large-scale population studies.
In summary, PPARα L162V polymorphism seems
to be selectively associated with HBV-induced
HCC but not with HCV-induced HCC. Further
studies are needed to determine whether this
polymorphism selectively changes cellular respon-
ses to exogenous stimuli (e.g. HBV viral protein)
and/or cellular factors, thus promoting tumor de-
velopment.
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Pt. no Etiology Tumor size Met PVT
1 B Diffuse - -
2 B Multiple + +
(greatest length 8 cm)
3 B Multiple - -
(1-2 cm)
4 B+D Solitary - -
(5x5x4 cm)
5 B Multiple + +
(greatest length 5 cm)
6 B Multiple - -
(greatest length 4 cm)
PVT: Portal vein thrombosis. Met: Metastasis.
Table 3. Characteristics of patients having L162V poly-
morphism
REFERENCES
1. Rao MS, Reddy JK. Peroxisomal ß-oxidation and steatohe-
patitis. Semin Liver Dis 2001;21:43-55.
2. Issemann I, Green S. Activation of a member of the steroid
hormone receptor superfamily by peroxisome proliferators.
Nature 1990;347:645-50.
3. Desvergne B, Wahli BW. Peroxisome proliferator-activated
receptors: nuclear control of metabolism. Endocr Rev
1999;20:649-88.
4. Akb›y›k F, Ray DM, Bozkaya H, Demirpençe E. Ligand and
species dependent activation of PPARα. Cell Physiol Bioc-
hem 2004;14:269-76.
5. Akb›y›k F, Ç›nar K, Demirpençe E, et al. Ligand induced
expression of peroxisome proliferator-activated receptor
alpha and activation of fatty acid oxidation enzymes in
fatty liver. Eur J Clin Invest 2004;34:429-35. 
6. Hashimoto T, Cook WS, Qi C, et al. Defect in peroxisome
proliferator-activated receptor alpha-inducible fatty acid
oxidation determines the severity of hepatic steatosis in
response to fasting. J Biol Chem 2000;275:28918-28.
7. Johnson EF, Palmer CN, Griffin KJ, Hsu MH. Role of the
peroxisome proliferator-activated receptor in cytochrome
P450 4A gene regulation. FASEB J 1996;10:1241-8.
8. Lee SS, Pineau T, Drago J, et al. Targeted disruption of the
alpha isoform of the peroxisome proliferator-activated re-
ceptor gene in mice results in abolishment of the pleiotro-
pic effects of peroxisome proliferators. Mol Cell Biol 1995;
15:3012-22.
9. Mandard S, Müller M, Kersten S. Peroxisome proliferator-
activated receptor α target genes. Cell Mol Life Sci
2004;61:393-416.
10. Koike K, Tsutsumi T, Fujie H, et al. Molecular mechanism
of viral hepatocarcinogenesis. Oncology 2002;62:29-37.
11. Chisari FV. Viruses, immunity, and cancer: lessons from
hepatitis B. Am J Pathol 2000;156:1118-32.
12. Gonzales FJ. The peroxisome proliferators-activated recep-
tor α: role in hepatocarcinogenesis. Mol Cell Endocrinol
2002;193:71-9.
13. Roberts-Thomson SJ. Peroxisome proliferators-activated
receptors in tumorigenesis: targets of tumour promotion
and treatment. Immunol Cell Biol 2000;78:436-41.
14. Reddy JK, Azarnoff DL. Hypolipidemic hepatic peroxisome
proliferators form a novel class of chemical carcinogens.
Nature 1980;283:397-8.
15. Reddy JK. Nonalcoholic steatosis and steatohepatitis III.
Peroxisomal ß-oxidation, PPAR alpha, and steatohepatitis.
Am J Physiol Gastrointest Liver Physiol 2001;281:G1333-
9.
16. Fan CY, Pan J, Usuda N, et al. Steatohepatitis, spontaneo-
us peroxisome proliferation and liver tumors in mice lac-
king peroxisomal fatty acyl-CoA oxidase. J Biol Chem
1998;273:15639-45.
17. Fan CY, Pan J, Chu R, et al. Hepatocellular and hepatic pe-
roxisomal alterations in mice with a disrupted peroxisomal
fatty acyl-coenzyme A oxidase gene. J Biol Chem 1996;271:
24698-710.
18. Flavell DM, Pineda Torra I, Jamshidi Y, et al. Variation in
the PPAR alpha gene is associated with altered function in
vitro and plasma lipid concentrations in type II diabetic
subjects. Diabetologia 2000;43:673-80.
19. Vohl MC, Lepage P, Gaudet D, et al. Molecular scanning of
the human PPAR alpha gene: association of the L162V mu-
tation with hyperapobetalipoproteinemia. J Lipid Res
2000;41:945-52.
20. Tai ES, Demissie S, Cupples LA, et al. Association betwe-
en the PPAR alpha L162V polymorphism and plasma lipid
levels. The Framingham offspring study. Arterioscler
Thromb Vasc Biol 2002;22:805-10.
21. Robitaille J, Brouillette C, Houde A, et al. Association bet-
ween PPAR alpha-L162V polymorphism and components
of the metabolic syndrome. J Hum Genet 2004;49:482-9.
22. Verdi H, Koytak ES, Önder O, et al.  Peroxisome prolifera-
tor-activated receptor alpha L162V polymorphism in
NASH and genotype-1 HCV related liver steatosis. J Inves-
tig Med 2005 (in press).
23. Duffy JP, Vardanian A, Benjamin E, et al. Liver transplan-
tation criteria for hepatocellular carcinoma should be ex-
panded, a 22-year experience with 467 patients at UCLA.
Ann Surg 2007;246:502-11.
24. Evans D, Aberle J, Wendt D, et al. A polymorphism,
L162V, in the PPAR alpha gene is associated with lower
body mass index in patients with non-insulin-dependent
diabetes mellitus. J Mol Med 2001;79:198-204.
25. Gouni-Berthold I, Giannakidou E, Muller-Wieland D, et al.
Association between the PPAR alpha L162V polymorp-
hism, plasma lipoprotein levels, and atherosclerotic disea-
se in patients with diabetes mellitus type 2 and in non-di-
abetic controls. Am Heart J 2004;147:1117-24.
26. Sumanasekera WK, Tien ES, Turpey R, et al. Evidence
that peroxisome proliferator-activated receptor alpha is
complexed with 90-kDa heat shock protein and the hepati-
tis virus B X-associated protein 2. J Biol Chem 2003;278:
4467-73.
27. Huan B, Kosovsky MJ, Siddiqui A. Retinoid X receptor alp-
ha transactivates the hepatitis B enhancer 1 element by
forming a heterodimeric complex with the peroxisome pro-
liferator-activated receptor. J Virol 1995;69:547-51.
PPAR-α polymorphism in HCC 249
